A case report of sofosbuvir induced drug eruption and literature review

Sofosbuvir, a pan-genotypic antiviral agent, has emerged as a cornerstone in the treatment of chronic hepatitis C, offering significant efficacy. Despite its established therapeutic benefits, the drug's safety profile and the occurrence of adverse reactions are less documented due to its recent introduction to the market. Here we report a patient who experienced drug-induced eruption induced by two distinct sofosbuvir-containing regimens. The report includes a thorough analysis and discussion of the case, accompanied by a comprehensive literature review.